Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial. - Fukui S; Sumiyoshi R; Koga T; Hosogaya N; Narita S; Morimoto S; Kamisawa O; Kiya R; Katsube A; Yano S; Matsuyama K; Kato N; et al. (Modern rheumatology, 2026)